---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-066311"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:10:50.574644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells

## Summary
- In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.
- Initial CAR T administration eliminated 98% of lymphoma cells; resistant population emerged; MT-601 overcame resistance.
- MT-601 targets six antigens (including WT-1) vs. five in earlier TACTAL study, potentially offering more durable responses.
- FDA cleared IND for MT-601; Phase 1 trial in relapsed non-Hodgkin lymphoma initiated Q1 2023.

## SEC filing metadata
- accession: 0001104659-23-066311
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/0001104659-23-066311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/tm2317378d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-066311
- JSON: https://secwatch.observer/filing/0001104659-23-066311.json
- Plain text: https://secwatch.observer/filing/0001104659-23-066311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.